Folic Acid Supplementation in Patients with Elevated Homocysteine Levels
Introduction Folic acid is the most important dietary determinant of homocysteine (Hcy). Hcy serves as a critical intermediate in methylation reactions. It is created from methionine and either converted back to methionine or transformed into cysteine. This process is aided through several enzymes and three vitamins, folic acid, B12, and B6. Daily supplementation with 0.5–5.0 mg of folic acid typically lowers plasma Hcy levels by approximately 25%. Hyperhomocysteinemia is a known risk factor for coronary artery disease. In this regard, elevated levels of Hcy have been found in a majority of patients with vascular disease. Methods A literature review of folic acid supplementation for various disease states including cardiovascular disease was conducted. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Results In this review, we discuss the biochemistry of folic acid, Hcy biosynthesis, Hcy and hydrogen sulfide bioavailability, pathogenesis of hyperhomocysteinemia and its role as a risk factor for disease, and treatment studies with folic acid supplementation in disease states. Conclusion Folic acid supplementation should be recommended to any patient who has an elevated Hcy level, and this level should be measured and treated at an early age, since folic acid is easily obtained and may likely reduce vascular disease and other deleterious pathologic processes in high-risk populations..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Advances in therapy - 37(2020), 10 vom: 26. Aug., Seite 4149-4164 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaye, Alan D. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Coronary artery disease |
|---|
| doi: |
10.1007/s12325-020-01474-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR040989445 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR040989445 | ||
| 003 | DE-627 | ||
| 005 | 20230519162853.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-020-01474-z |2 doi | |
| 035 | |a (DE-627)SPR040989445 | ||
| 035 | |a (SPR)s12325-020-01474-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Kaye, Alan D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Folic Acid Supplementation in Patients with Elevated Homocysteine Levels |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction Folic acid is the most important dietary determinant of homocysteine (Hcy). Hcy serves as a critical intermediate in methylation reactions. It is created from methionine and either converted back to methionine or transformed into cysteine. This process is aided through several enzymes and three vitamins, folic acid, B12, and B6. Daily supplementation with 0.5–5.0 mg of folic acid typically lowers plasma Hcy levels by approximately 25%. Hyperhomocysteinemia is a known risk factor for coronary artery disease. In this regard, elevated levels of Hcy have been found in a majority of patients with vascular disease. Methods A literature review of folic acid supplementation for various disease states including cardiovascular disease was conducted. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Results In this review, we discuss the biochemistry of folic acid, Hcy biosynthesis, Hcy and hydrogen sulfide bioavailability, pathogenesis of hyperhomocysteinemia and its role as a risk factor for disease, and treatment studies with folic acid supplementation in disease states. Conclusion Folic acid supplementation should be recommended to any patient who has an elevated Hcy level, and this level should be measured and treated at an early age, since folic acid is easily obtained and may likely reduce vascular disease and other deleterious pathologic processes in high-risk populations. | ||
| 650 | 4 | |a Coronary artery disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Folic acid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Heart disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Homocysteine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hyperhomocysteinemia |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Jeha, George M. |e verfasserin |4 aut | |
| 700 | 1 | |a Pham, Alex D. |e verfasserin |4 aut | |
| 700 | 1 | |a Fuller, Mitchell C. |e verfasserin |4 aut | |
| 700 | 1 | |a Lerner, Zachary I. |e verfasserin |4 aut | |
| 700 | 1 | |a Sibley, Gerald T. |e verfasserin |4 aut | |
| 700 | 1 | |a Cornett, Elyse M. |e verfasserin |4 aut | |
| 700 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Kevil, Christopher G. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Tarporley : Springer Healthcare Communications, 2000 |g 37(2020), 10 vom: 26. Aug., Seite 4149-4164 |w (DE-627)SPR024919926 |w (DE-600)2421646-X |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g number:10 |g day:26 |g month:08 |g pages:4149-4164 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12325-020-01474-z |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |e 10 |b 26 |c 08 |h 4149-4164 | ||